loading page

Interleukin-17A (IL-17A): the silent amplifier of COVID-19
  • +1
  • Francesco Maione,
  • Gian Casillo,
  • Federica Raucci,
  • Mariarosaria Bucci
Francesco Maione
University of Naples Federico II Department of Pharmacy
Author Profile
Gian Casillo
University of Naples Federico II School of Medicine and Surgery
Author Profile
Federica Raucci
University of Naples Federico II Department of Pharmacy
Author Profile
Mariarosaria Bucci
University of Naples Federico II Department of Pharmacy
Author Profile

Abstract

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated levels of interleukin-17A (IL-17A) and disease severity and progression. Considering that per se IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, this cytokine can represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.